To amend the Federal Food, Drug, and Cosmetic Act to provide for notification by manufacturers of critical drugs of increased demand, and for other purposes.
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
This bill strengthens the FDA ability to prevent drug shortages by requiring pharmaceutical manufacturers to provide earlier and more comprehensive notifications about potential supply disruptions. It expands reporting requirements to cover not just production interruptions, but also demand increases, export restrictions, and other circumstances that could lead to shortages.
Who Benefits and How
Healthcare providers and patients benefit from improved visibility into drug supply chains and earlier warnings about potential shortages. The FDA gains more comprehensive information about drug supply vulnerabilities, including detailed data on active pharmaceutical ingredient (API) sources. Domestic pharmaceutical manufacturers with transparent supply chains may gain competitive advantages as supply chain visibility becomes more important.
Who Bears the Burden and How
Pharmaceutical manufacturers face increased compliance burdens, including biannual supply chain reporting (previously annual), mandatory disclosure of API suppliers and sources, and faster notification requirements (within 10 business days for demand-related circumstances). Foreign API suppliers may face scrutiny as their identities become part of mandatory FDA reporting.
Key Provisions
- Requires manufacturers to notify FDA of any circumstance (demand surges, export restrictions) likely to cause shortages, not just production interruptions
- Mandates disclosure of active pharmaceutical ingredient sources and alternative suppliers when relevant to supply disruptions
- Increases supply chain reporting from annual to biannual (March and September)
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers.
At a Glance
What This Bill Does
Strengthens FDA notification and reporting requirements to prevent drug shortages by requiring earlier manufacturer notifications about supply disruptions and more detailed supply chain reporting.
Key Policy Areas
Healthcare, Pharmaceuticals, Supply Chain, Regulatory Compliance
Primary Purpose
Strengthens FDA notification and reporting requirements to prevent drug shortages by requiring earlier manufacturer notifications about supply disruptions and more detailed supply chain reporting.
Policy Domains
Drug Shortage Prevention Act of 2025
Identified Gains
Contextual inference, no direct clause citation- Healthcare providers
- Patients
- FDA
- Domestic pharmaceutical supply chain
Contextual inference, no direct clause citation
Identified Costs
Contextual inference, no direct clause citation- Pharmaceutical manufacturers
- API suppliers
Contextual inference, no direct clause citation
Sponsors
Legislative Progress
IntroducedMs. Klobuchar (for herself, Ms. Collins, Ms. Warren, Ms. Murkowski, …
Stakeholder Effects
cui bono?How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.
Active pharmaceutical ingredient (API) suppliers, Pharmaceutical drug manufacturers of covered drugs, Pharmaceutical drug manufacturers registered with FDA
Patients requiring life-supporting or life-sustaining drugs
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
- "the_secretary"
- → Secretary of Health and Human Services
Key Definitions
Terms defined in this bill
A drug intended for human use that is: (A) life-supporting, life-sustaining, or intended for prevention/treatment of debilitating disease (including emergency/surgical drugs and those critical during public health emergencies); (B) not a radiopharmaceutical or other Secretary-designated product; and (C) not a biological product unless FDA regulations provide otherwise.
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology